ArticleMedical oncology (Northwood, London, England)2025
Effects of PELP1 on proliferation, metastasis and angiogenesis of epithelial ovarian cancer.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The PELP1 Pathway and Its Importance in Cancer Treatment.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
To investigate the effects of Proline-, Glutamic acid- and Leucine-rich protein 1(PELP1) on the biological behaviors of epithelial ovarian cancer (EOC) cells and its role in promoting angiogenesis through the regulation of VEGFA expression and secretion. Bioinformatics analysis was performed to evaluate the correlation between PELP1 and VEGFA. The expression levels and subcellular localization of PELP1 and VEGFA in EOC cell lines were assessed using Western blot (WB), quantitative real-time PCR (qRT-PCR) and immunofluorescence. Functional assays, including EdU proliferation assays, wound healing assays, Transwell invasion assays and WB were conducted to examine the effects of PELP1 overexpression. Conditioned medium (CM) from PELP1-overexpression cells was used to culture human umbilical vein endothelial cells (HUVECs) and angiogenesis was evaluated using Transwell migration, wound healing, and tube formation assays. VEGFA expression and secretion were analyzed by immunofluorescence, qRT-PCR, and enzyme-linked immunosorbent assays (ELISA). WB and ELISA were performed to validate the effects of the VEGFA inhibitor (HY-117661) on both the expression and secretion of VEGFA. Functional rescue experiments, including migration and tube formation assays, were conducted to verify whether PELP1 regulated angiogenesis through VEGFA. Bioinformatics analysis revealed a positive correlation between PELP1 and VEGFA. Both proteins were significantly upregulated in EOC cells compared to normal ovarian epithelial cells. Overexpression of PELP1 enhanced proliferation, migration, invasion and the expression of metastasis-associated proteins, including N-cadherin and Vimentin. Additionally, PELP1 upregulated VEGFA expression and secretion, which subsequently promoted HUVEC migration and angiogenesis. PELP1 promotes EOC progression by enhancing cellular proliferation, metastasis and angiogenesis through the regulation of VEGFA. These findings suggest that PELP1 could serve as a potential therapeutic target for EOC.
Indexed as
Identifiers
40715657What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.